Adenovirus vectors have shown promise for vaccines, but one key hurdle is preexisting immunity to these viruses in humans. The VRC has been investigating the use of priming with either DNA or adenovirus vaccines and the use of alternate adenoviral serotypes or modified adenoviral vectors to overcome prior immunity. During the past year, the VRC has evaluated chimpanzee adenovirus vectors (ChAd3 and ChAd63) to analyze their ability to induce an immune response as compared to Ad5 and in the presence of Ad5 seropostivity. Several of these vectors are being further tested to evaluate their potential use in clinical trials. Plans are in progress to produce cGMP lots of a ChAd HIV vaccine.
| Sullivan, Nancy J; Hensley, Lisa; Asiedu, Clement et al. (2011) CD8+ cellular immunity mediates rAd5 vaccine protection against Ebola virus infection of nonhuman primates. Nat Med 17:1128-31 |
| Cheng, Cheng; Gall, Jason G D; Nason, Martha et al. (2010) Differential specificity and immunogenicity of adenovirus type 5 neutralizing antibodies elicited by natural infection or immunization. J Virol 84:630-8 |
| Ko, Sung-Youl; Cheng, Cheng; Kong, Wing-Pui et al. (2009) Enhanced induction of intestinal cellular immunity by oral priming with enteric adenovirus 41 vectors. J Virol 83:748-56 |
| Sun, Yue; Bailer, Robert T; Rao, Srinivas S et al. (2009) Systemic and mucosal T-lymphocyte activation induced by recombinant adenovirus vaccines in rhesus monkeys. J Virol 83:10596-604 |
| Wang, Lingshu; Cheng, Cheng; Ko, Sung-Youl et al. (2009) Delivery of human immunodeficiency virus vaccine vectors to the intestine induces enhanced mucosal cellular immunity. J Virol 83:7166-75 |
